Notice: This company has been marked as potentially delisted and may not be actively trading. Bioanalytical Systems (BASI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends BASI vs. PIRS, NOTV, LUNA, ONMD, BIAF, AIKI, FOXO, ISPC, DKDCA, and PGENShould you be buying Bioanalytical Systems stock or one of its competitors? The main competitors of Bioanalytical Systems include Pieris Pharmaceuticals (PIRS), Inotiv (NOTV), Luna Innovations (LUNA), OneMedNet (ONMD), bioAffinity Technologies (BIAF), AIkido Pharma (AIKI), FOXO Technologies (FOXO), iSpecimen (ISPC), Data Knights Acquisition (DKDCA), and Precigen (PGEN). Bioanalytical Systems vs. Pieris Pharmaceuticals Inotiv Luna Innovations OneMedNet bioAffinity Technologies AIkido Pharma FOXO Technologies iSpecimen Data Knights Acquisition Precigen Pieris Pharmaceuticals (NASDAQ:PIRS) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Is PIRS or BASI more profitable? Bioanalytical Systems has a net margin of -7.75% compared to Pieris Pharmaceuticals' net margin of -39.71%. Bioanalytical Systems' return on equity of -42.74% beat Pieris Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pieris Pharmaceuticals-39.71% -80.93% -59.55% Bioanalytical Systems -7.75%-42.74%-6.38% Does the MarketBeat Community prefer PIRS or BASI? Pieris Pharmaceuticals received 150 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 60.30% of users gave Pieris Pharmaceuticals an outperform vote while only 38.55% of users gave Bioanalytical Systems an outperform vote. CompanyUnderperformOutperformPieris PharmaceuticalsOutperform Votes27860.30% Underperform Votes18339.70% Bioanalytical SystemsOutperform Votes12838.55% Underperform Votes20461.45% Which has stronger earnings & valuation, PIRS or BASI? Bioanalytical Systems has higher revenue and earnings than Pieris Pharmaceuticals. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPieris Pharmaceuticals$42.81M0.49-$24.54M-$12.10-1.30Bioanalytical Systems$60.47M0.59-$4.68M-$0.35-9.17 Do insiders & institutionals hold more shares of PIRS or BASI? 40.1% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are owned by institutional investors. 6.4% of Pieris Pharmaceuticals shares are owned by insiders. Comparatively, 11.5% of Bioanalytical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer PIRS or BASI? In the previous week, Pieris Pharmaceuticals had 2 more articles in the media than Bioanalytical Systems. MarketBeat recorded 2 mentions for Pieris Pharmaceuticals and 0 mentions for Bioanalytical Systems. Pieris Pharmaceuticals' average media sentiment score of 0.21 beat Bioanalytical Systems' score of 0.00 indicating that Pieris Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Pieris Pharmaceuticals Neutral Bioanalytical Systems Neutral Which has more risk and volatility, PIRS or BASI? Pieris Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. SummaryBioanalytical Systems beats Pieris Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Bioanalytical Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BASI vs. The Competition Export to ExcelMetricBioanalytical SystemsCommercial Physical Research IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.73M$4.23B$5.10B$8.84BDividend YieldN/A1.65%5.04%4.07%P/E Ratio-7.6439.0995.1214.22Price / Sales0.5955.351,217.3088.42Price / Cash558.4023.4239.4936.27Price / Book4.653.376.976.37Net Income-$4.68M$139.66M$118.73M$225.56M Bioanalytical Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BASIBioanalytical SystemsN/A$3.21+15.1%N/A+22.9%$35.73M$60.47M-7.64397Analyst ForecastGap UpHigh Trading VolumePIRSPieris Pharmaceuticals1.6396 of 5 stars$15.79-1.4%N/A-10.4%$20.84M$42.81M-1.32140Analyst UpgradeNews CoverageGap DownNOTVInotiv1.5976 of 5 stars$3.45+7.5%$5.92+71.5%+41.4%$89.70M$572.42M0.002,055News CoverageLUNALuna Innovations2.2248 of 5 stars$1.66+2.1%$8.00+380.6%-71.9%$56.53M$109.50M0.00337ONMDOneMedNetN/A$0.84+0.0%N/A-82.3%$23.67M$1.02M0.002BIAFbioAffinity Technologies2.4464 of 5 stars$1.22-3.6%$6.00+390.2%-11.8%$19.08M$2.53M-1.5510Gap UpAIKIAIkido PharmaN/A$1.57-3.7%N/A-18.5%$8.61M$10,000.00-0.404Gap DownFOXOFOXO TechnologiesN/A$0.59-10.5%N/A+117.4%$8.05M$140,000.000.003News CoverageGap UpISPCiSpecimen0.0815 of 5 stars$4.60-0.2%N/A+694.8%$4.42M$9.93M0.0060DKDCAData Knights AcquisitionN/A$0.84-1.2%N/A-82.1%$4.35MN/A-4.422PGENPrecigen3.7857 of 5 stars$0.92+10.0%$7.00+660.9%-30.9%$269.44M$6.22M0.00202Analyst Revision Related Companies and Tools Related Companies Pieris Pharmaceuticals Competitors Inotiv Competitors Luna Innovations Competitors OneMedNet Competitors bioAffinity Technologies Competitors AIkido Pharma Competitors FOXO Technologies Competitors iSpecimen Competitors Data Knights Acquisition Competitors Precigen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BASI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioanalytical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioanalytical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
